Do PPAR-Gamma Agonists Have a Future in Parkinson’s Disease Therapy?
Do PPAR-Gamma Agonists Have a Future in Parkinson’s Disease Therapy?
About this item
Full title
Author / Creator
Publisher
Cairo, Egypt: Hindawi Limiteds
Journal title
Language
English
Formats
Publication information
Publisher
Cairo, Egypt: Hindawi Limiteds
Subjects
More information
Scope and Contents
Contents
Thiazolidinediones (TZDs) are peroxisome proliferator-activated receptor (PPAR)-γ agonists commonly used as insulin-sensitizing drugs for the treatment of type 2 diabetes. In the last decade, PPAR-γ agonists have received increasing attention for their neuroprotective properties displayed in a variety of neurodegenerative diseases, including Parkin...
Alternative Titles
Full title
Do PPAR-Gamma Agonists Have a Future in Parkinson’s Disease Therapy?
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_47b1a529b0074eeb8cb09b53d02b2b6c
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_47b1a529b0074eeb8cb09b53d02b2b6c
Other Identifiers
ISSN
2042-0080,2090-8083
E-ISSN
2042-0080
DOI
10.4061/2011/689181
